Stockreport

Immunome Reports Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]

Immunome, Inc.  (IMNM) 
PDF New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 IM-1021 Phase 1 ongoing with initial data expected in 2026 Thre [Read more]